当前位置:首页>产品中心>单抗/多抗>HEK293T SARS-CoV-2 Spike (PP) Stable Cell Line|HEK293T SARS-CoV-2刺突(PP)稳定细胞系(靶标:新冠病毒刺突蛋白(PP突变)稳定表达细胞系)

HEK293T SARS-CoV-2 Spike (PP) Stable Cell Line|HEK293T SARS-CoV-2刺突(PP)稳定细胞系(靶标:新冠病毒刺突蛋白(PP突变)稳定表达细胞系)

  • 货号:RB9TVK474818
  • 价格:面议
  • 点击:392

产品介绍

产品参数

宿主种属HEK293T
应用FCM
靶标SARS-CoV-2 Spike (PP)
稳定性和储存Frozen in liquid nitrogen.
登录号P0DTC2
背景信息

Spike glycoprotein (SARS-CoV-2 Spike (PP)) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors.

1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651
2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444
3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086
4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887
5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877
6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306
7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715
8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763
9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294
10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293
产品特性Growth Properties: Adherent; Selection Marker: Puromycin (1 μg/mL)
种属Viral (SARS-CoV-2)
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 401
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 361
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 345
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 368
Anti-Durvalumab Non-Neutralizing Recombinant Antibody |程度伐利尤单抗非中和重组抗体(靶标:度伐利尤单抗非中和抗体) 645
Anti-Durvalumab Non-Neutralizing Recombinant Antibody |抗度伐利尤单抗非中和重组抗体(靶标:度伐利尤单抗非中和抗体) 613
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 406
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 457
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 395
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 386
Anti-Atezolizumab Non-Neutralizing Recombinant Antibody |抗阿替利珠单抗非中和重组抗体(靶标:阿替利珠单抗非中和抗体) 443
Anti-Atezolizumab Non-Neutralizing Recombinant Antibody |抗阿替利珠单抗非中和重组抗体(靶标:阿替利珠单抗非中和抗体) 408
Anti-Atezolizumab Neutralizing Recombinant Antibody |抗阿替利珠单抗中和重组抗体(靶标:阿替利珠单抗中和抗体) 395
Anti-Atezolizumab Neutralizing Recombinant Antibody |抗阿替利珠单抗中和重组抗体(靶标:阿替利珠单抗中和抗体) 446
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 583
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 392
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 339
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 321
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 301
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 316
总计 33037 个记录,共 1652 页,当前第 1647 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00